

Table SII. Summary of systemic treatment and chemotherapy given (18 patients)

Drug	Patients treated, <i>n</i>	Current MF stage	Dosage	Stable disease, <i>n</i>	Treatment duration, median/mean	Comment
Acitretin	5	IA–IB	20–25 mg/day	5	20/28 months	
Isotretinoin	6	IA–IB	0.7 mg/kg/day	5	12/12 months	
Bexarotene	3	IIA–IIB	250–265 mg/m <sup>2</sup> /day	1	7/12 months	<sup>1</sup>
Interferon- $\alpha$	2	IB	3 million IU 3/week	1	2 months	<sup>2</sup>
Methotrexate	10	IB–IIIA	15–22.5 mg/week	7	6/9 months	
Chlorambucil	4	IIA–IIIA	0.1–0.2 mg/kg/day	0	<1 month	<sup>3</sup>
Cyclophosphamide	4	IIA–IVA2	Standard regimen, 3–6 cycles	0	3.5/3.5 cycles	<sup>4</sup>
Gemcitabine	4	IIA–IVA2	1,200 mg/m <sup>2</sup> /day 3–6 cycles	0	5/4.5 cycles	<sup>4</sup>
Pegylated doxorubicin	2	IIA–IIIA	20 mg/m <sup>2</sup> every third week	0	2 cycles	<sup>5</sup>
Alemtuzumab	4	IIA–IVB	10–30 mg 3/week	1	1.5/5 months	<sup>6</sup>

<sup>1</sup>Treatment with bexarotene in all patients was below aimed dosage of 300 mg/m<sup>2</sup>/day due to side-effects. <sup>2</sup>One patient stopped treatment with interferon- $\alpha$  due to thyreotoxicosis after one month. <sup>3</sup>Aimed dosage of chlorambucil was 4–8 weeks combined with tapering dosages of prednisolone or prednisone. No treatment lasted more than 4 weeks due to infections. <sup>4</sup>Chemotherapy in IIA patient due to large cell transformation. All patients showed progress of disease during therapy. <sup>5</sup>Severe hand and foot dermatitis with pegylated doxorubicin resulting in suboptimal amount of cycles.

<sup>6</sup>Only one patient with alemtuzumab tolerated treatment; 3 patients stopped treatment due to infections.